10.31.24 -- Incorporating AI-Driven Solutions Into Clinical Trial Processes

In clinical research, as with many industries, artificial intelligence (AI) is met with both excitement and trepidation. The utility of AI in drug development and clinical data workflows is making it an area of interest for pharmaceutical companies. Explore how the impact of AI is starting to be felt across the pharmaceutical industry.

How could leveraging AI technologies, including machine learning (ML) and generative AI (GenAI), enable your company to streamline processes from drug discovery to post-launch? Learn about the next generation of AI technology and how GenAI and EdgeAI platforms, Quantum ML, and Quantum AI could improve your clinical trials.

To fully harness AI solutions, organizations must foster collaboration across clinical, regulatory, data management, and IT teams. By working together and sharing knowledge, they can integrate AI into existing workflows and ensure all stakeholders are aligned on AI adoption goals and objectives.

Synthetic data is a form of generative artificial intelligence (AI) being used in many industries to detect fraud, improve testing and validation, and facilitate training and automation. In the life sciences, AI is especially valuable for enhancing datasets and increasing diversity in clinical trials.